Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Accumulated Expenses (2016 - 2020)

Historic Other Accumulated Expenses for Myriad Genetics (MYGN) over the last 7 years, with Q2 2020 value amounting to $22.4 million.

  • Myriad Genetics' Other Accumulated Expenses rose 2444.44% to $22.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $22.4 million, marking a year-over-year increase of 2444.44%. This contributed to the annual value of $22.4 million for FY2020, which is 2444.44% up from last year.
  • According to the latest figures from Q2 2020, Myriad Genetics' Other Accumulated Expenses is $22.4 million, which was up 2444.44% from $4.3 million recorded in Q1 2020.
  • Myriad Genetics' 5-year Other Accumulated Expenses high stood at $22.4 million for Q2 2020, and its period low was $4.3 million during Q1 2020.
  • For the 5-year period, Myriad Genetics' Other Accumulated Expenses averaged around $14.0 million, with its median value being $14.0 million (2017).
  • As far as peak fluctuations go, Myriad Genetics' Other Accumulated Expenses surged by 8481.01% in 2016, and later crashed by 8009.26% in 2020.
  • Quarter analysis of 5 years shows Myriad Genetics' Other Accumulated Expenses stood at $13.7 million in 2016, then rose by 13.87% to $15.6 million in 2017, then increased by 13.46% to $17.7 million in 2018, then plummeted by 53.67% to $8.2 million in 2019, then skyrocketed by 173.17% to $22.4 million in 2020.
  • Its last three reported values are $22.4 million in Q2 2020, $4.3 million for Q1 2020, and $8.2 million during Q4 2019.